Coronary interventions

Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials

EuroIntervention 2015;11:196-203 published online ahead of print August 2014. DOI: 10.4244/EIJY14M08_01

Salvatore Cassese
Salvatore Cassese1, MD; Robert A. Byrne1*, MB, BCh, PhD; Karl-Ludwig Laugwitz2,3, MD; Heribert Schunkert1,3, MD; Peter B. Berger4, MD; Adnan Kastrati1,2,3, MD
1. Deutsches Herzzentrum, Technische Universität München, Munich, Germany; 2. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; 3. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Al

Aims: Current recommendations on the use of bivalirudin in patients treated with percutaneous coronary intervention (PCI) are mostly based on trials comparing bivalirudin versus heparin p

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

anticoagulationbivalirudinheparinmeta-analysispercutaneous coronary intervention
Read next article
Implantation of a novolimus-eluting bioresorbable scaffold with a strut thickness of 100 µm showing evidence of self-correction

Latest news